正在加载公司
Keep exploring
The themes Sanofi is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The themes it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And CompanyUS$1.36TA+
JNJJohnson & JohnsonUS$688.6BA+
MRKMerck & Co., Inc.US$364.3BA
NVSNovartis AGUS$306.3BA
AMGNAmgen Inc.US$251.9BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A
怎么赚钱
- Prescription medicines
- Vaccines
竞争对手
卖什么5
Dupixent
A biologic medicine used for several conditions; the call mentions its approval for chronic spontaneous urticaria in children.
ALTUVIIIO
A medicine for hemophilia A, a disorder that affects blood clotting.
AYVAKIT
A medicine used to treat systemic mastocytosis, a rare disease.
再显示 2 项
Sarclisa
A medicine for multiple myeloma, a cancer of plasma cells.
Wayrilz
A medicine approved in Japan for immune thrombocytopenia, a condition involving low levels of platelets in the blood.
谁在买3
- Patients receive Sanofi medicines through healthcare professionals who prescribe or administer them.
- People receive Sanofi vaccines through healthcare providers and public health programs.
- Pharmacies and clinics are involved in medicine access programs.
靠什么支撑，什么会击垮它
业务依赖什么
- 1Dupixent is developed with Regeneron under an alliance that Sanofi describes as strategically important.
- 2Vaccine sales vary with seasonal demand, including the timing and strength of influenza seasons.
- 3Sanofi depends on clinical studies to show that medicines in development work well enough to advance.
可能出什么问题
- 1Sanofi says its global business exposes it to increased risks in specific areas.
- 2Clinical setbacks have included failed or discontinued studies involving Dupixent in lichen simplex chronicus, venglustat in Fabry disease, and other pipeline medicines.
- 3Sanofi and Regeneron have ongoing litigation over information sharing, while discussions about future collaboration continue without a reported agreement.
关于Sanofi
Sanofi makes prescription medicines and vaccines. Its medicines treat conditions including hemophilia A, systemic mastocytosis, and multiple myeloma. It also develops new medicines and vaccines through clinical trials.
- 总部
- Paris, France
- 成立于
- 1973 (founding year, high)
- 上市于
- NYSE
- 财年结束
- December 31
基于 Sanofi 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 该公司以 EUR 申报。数字按当前汇率 US$1.00 = 0.904810 EUR 换算为美元，并对所有期间一视同仁——因此增长和利润率属于公司本身，而不是汇率。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
